These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 38168532)
1. Patient-related factors influencing the effectiveness and safety of Janus Kinase inhibitors in rheumatoid arthritis: a real-world study. Martinez-Molina C; Gich I; Diaz-Torné C; Park HS; Feliu A; Vidal S; Corominas H Sci Rep; 2024 Jan; 14(1):172. PubMed ID: 38168532 [TBL] [Abstract][Full Text] [Related]
2. Real-world study comparing the efficacy of Janus kinase inhibitors in patients with difficult-to-treat rheumatoid arthritis. Hayashi S; Nakano N; Tsubosaka M; Kamenaga T; Kuroda Y; Matsumoto T; Yamada H; Nishimra K; Ueda Y; Saegusa J; Kuroda R Clin Rheumatol; 2024 Nov; 43(11):3285-3292. PubMed ID: 39243280 [TBL] [Abstract][Full Text] [Related]
3. Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study. Scheepers L; Yang Y; Chen YL; Jones G Semin Arthritis Rheum; 2024 Feb; 64():152314. PubMed ID: 38029717 [TBL] [Abstract][Full Text] [Related]
4. ToRaRI (Tofacitinib in Rheumatoid Arthritis a Real-Life experience in Italy): Effectiveness, safety profile of tofacitinib and concordance between patient-reported outcomes and physician's global assessment of disease activity in a retrospective study in Central-Italy. D'Alessandro F; Cazzato M; Laurino E; Morganti R; Bardelli M; Frediani B; Buongarzone C; Moroncini G; Guiducci S; Cometi L; Benucci M; Ligobbi F; Marotto D; Mosca M Clin Rheumatol; 2024 Feb; 43(2):657-665. PubMed ID: 38135860 [TBL] [Abstract][Full Text] [Related]
5. Real-world comparative study of drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis. Saito K; Yoshida S; Ebina H; Miyata M; Suzuki E; Kanno T; Sumichika Y; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Asano T; Sato S; Migita K PLoS One; 2024; 19(7):e0306714. PubMed ID: 38990897 [TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials. Sung YK; Lee YH J Clin Pharm Ther; 2021 Aug; 46(4):984-992. PubMed ID: 33600008 [TBL] [Abstract][Full Text] [Related]
7. Are all JAK inhibitors for the treatment of rheumatoid arthritis equivalent? An adjusted indirect comparison of the efficacy of tofacitinib, baricitinib, upadacitinib, and filgotinib. Vallez-Valero L; Gasó-Gago I; Marcos-Fendian Á; Garrido-Alejos G; Riera-Magallón A; Plaza Diaz A; Martinez-Molina C; Mangues-Bafalluy MA; Corominas H Clin Rheumatol; 2023 Dec; 42(12):3225-3235. PubMed ID: 37831336 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study). Aymon R; Mongin D; Bergstra SA; Choquette D; Codreanu C; De Cock D; Dreyer L; Elkayam O; Huschek D; Hyrich KL; Iannone F; Inanc N; Kearsley-Fleet L; Koca SS; Kvien TK; Leeb BF; Lukina G; Nordström DC; Pavelka K; Pombo-Suarez M; Rodrigues A; Rotar Z; Strangfeld A; Verschueren P; Westermann R; Zavada J; Courvoisier DS; Finckh A; Lauper K Ann Rheum Dis; 2024 Mar; 83(4):421-428. PubMed ID: 38071508 [TBL] [Abstract][Full Text] [Related]
9. Adverse reactions to Janus kinase inhibitors: Study of their incidence and predictive factors in patients with rheumatoid arthritis. Martinez-Molina C; Guardiola Tey JM; Ruiz-Ramos J; Feliu A; Puig-Campmany M; Vidal S; Corominas H Med Clin (Barc); 2024 Oct; 163(8):391-396. PubMed ID: 39003114 [TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670 [TBL] [Abstract][Full Text] [Related]
11. Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports. Goldman A; Galper BL; Druyan A; Grossman C; Sharif K; Shechtman L; Moshkovits Y; Lahat A; Ben-Zvi I Semin Arthritis Rheum; 2024 Aug; 67():152461. PubMed ID: 38772185 [TBL] [Abstract][Full Text] [Related]
12. Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Onishi A; Jinno S; Hara R; Son Y; Amuro H; Takeuchi T; Yoshikawa A; Katayama M; Yamamoto K; Okita Y; Hirao M; Etani Y; Kumanogoh A; Okada S; Nakata K Sci Rep; 2022 Jan; 12(1):134. PubMed ID: 34997059 [TBL] [Abstract][Full Text] [Related]
13. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review. Jegatheeswaran J; Turk M; Pope JE Immunotherapy; 2019 Jun; 11(8):737-754. PubMed ID: 30955397 [TBL] [Abstract][Full Text] [Related]
14. Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study. Ebina K; Hashimoto M; Yamamoto W; Hirano T; Hara R; Katayama M; Onishi A; Nagai K; Son Y; Amuro H; Yamamoto K; Maeda Y; Murata K; Jinno S; Takeuchi T; Hirao M; Kumanogoh A; Yoshikawa H Arthritis Res Ther; 2019 Apr; 21(1):91. PubMed ID: 30971306 [TBL] [Abstract][Full Text] [Related]
15. Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study. Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Takeuchi T; Nagai K; Son Y; Amuro H; Onishi A; Jinno S; Hara R; Katayama M; Yamamoto K; Kumanogoh A; Hirao M Clin Rheumatol; 2020 Sep; 39(9):2563-2572. PubMed ID: 32162152 [TBL] [Abstract][Full Text] [Related]
16. Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review. Mori S; Ogata F; Tsunoda R Clin Rheumatol; 2021 Nov; 40(11):4457-4471. PubMed ID: 34554329 [TBL] [Abstract][Full Text] [Related]
17. Real-world Effectiveness and Safety of JAK Inhibitors in Rheumatoid Arthritis: A Single-centre Study. González Mazarío R; Fragío Gil JJ; Ivorra Cortés J; Grau García E; Cañada Martínez AJ; González Puig L; Negueroles Albuixech RM; Román Ivorra JA Reumatol Clin (Engl Ed); 2022 Nov; 18(9):523-530. PubMed ID: 36309409 [TBL] [Abstract][Full Text] [Related]
18. Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study. Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Onishi A; Jinno S; Hara R; Son Y; Amuro H; Takeuchi T; Yoshikawa A; Katayama M; Yamamoto K; Hirao M; Okita Y; Kumanogoh A; Nakata K Clin Rheumatol; 2021 Jul; 40(7):2673-2680. PubMed ID: 33515115 [TBL] [Abstract][Full Text] [Related]
19. [Janus kinase inhibitors]. Witte T Z Rheumatol; 2022 Mar; 81(2):94-99. PubMed ID: 34820733 [TBL] [Abstract][Full Text] [Related]
20. Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naïve patients with rheumatoid arthritis. Sung YK; Lee YH Z Rheumatol; 2021 Nov; 80(9):889-898. PubMed ID: 32970188 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]